Literature DB >> 23774633

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.

K Takahashi1, E Jabbour, X Wang, R Luthra, C Bueso-Ramos, K Patel, S Pierce, H Yang, Y Wei, N Daver, S Faderl, F Ravandi, Z Estrov, J Cortes, H Kantarjian, G Garcia-Manero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23774633     DOI： 10.1038/leu.2013.165

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  23 in total

1.  Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.

Authors:  Manja Meggendorfer; Andreia de Albuquerque; Niroshan Nadarajah; Tamara Alpermann; Wolfgang Kern; Kimberly Steuer; Karolína Perglerová; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

2.  Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Authors:  Prajwal Boddu; Hagop M Kantarjian; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Kapil N Bhalla; Naval Daver; Courtney D DiNardo; Christopher B Benton; Koichi Takahashi; Zeev Estrov; Sherry R Pierce; Michael Andreeff; Jorge E Cortes; Tapan M Kadia
Journal:  Blood Adv       Date:  2017-07-19

Review 3.  Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.

Authors:  James A Kennedy; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

Review 4.  Genetics of progression from MDS to secondary leukemia.

Authors:  Andrew J Menssen; Matthew J Walter
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 5.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.

Authors:  Adam S Sperling; Christopher J Gibson; Benjamin L Ebert
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

6.  Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.

Authors:  Talha Badar; Jorge E Cortes; Farhad Ravandi; Susan O'Brien; Srdan Verstovsek; Guillermo Garcia-Manero; Hagop Kantarjian; Gautam Borthakur
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-02-19

7.  Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.

Authors:  Andrew J Menssen; Ajay Khanna; Christopher A Miller; Sridhar Nonavinkere Srivatsan; Gue Su Chang; Jin Shao; Joshua Robinson; Michele O'Laughlin; Catrina C Fronick; Robert S Fulton; Kimberly Brendel; Sharon E Heath; Raya Saba; John S Welch; David H Spencer; Jacqueline E Payton; Peter Westervelt; John F DiPersio; Daniel C Link; Matthew J Schuelke; Meagan A Jacoby; Eric J Duncavage; Timothy J Ley; Matthew J Walter
Journal:  Blood Cancer Discov       Date:  2022-07-06

Review 8.  Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.

Authors:  Marie Anne Hospital; Norbert Vey
Journal:  Curr Oncol Rep       Date:  2020-01-23       Impact factor: 5.075

9.  Clinical and genetic predictors of prognosis in myelodysplastic syndromes.

Authors:  Rafael Bejar
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

10.  Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

Authors:  Talha Badar; Keyur P Patel; Philip A Thompson; Courtney DiNardo; Koichi Takahashi; Monica Cabrero; Gautam Borthakur; Jorge Cortes; Marina Konopleva; Tapan Kadia; Zach Bohannan; Sherry Pierce; Elias J Jabbour; Farhad Ravandi; Naval Daver; Raja Luthra; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Leuk Res       Date:  2015-10-19       Impact factor: 3.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.